Eli Lilly has formed a partnership with Hong Kong's Metis TechBio worth up to $1.1 billion, gaining access to an AI drug delivery platform designed to improve therapeutic performance of drugs carried by lipid nanoparticles. The collaboration will center on Metis' ionizable lipid discovery and optimization platform called AiLNP, which the company touts as the “world's first and only de novo lipid generation algorithm,” relying on a large lipid library, end-to-end screening and a lipid language mo

NIGMS SBIR Phase II award will support development of an AI-powered metabolomics foundation model designed to unify insights across metabolomics data and accelerate therapeutic discovery through Sinopia's LEADS® platform Sinopia Biosciences, Inc., a biotechnology company leveraging multi-omics data, high-throughput screening, and artificial intelligence to identify and develop first-in-class therapies for diseases with significant unmet need, today announced it has been awarded a $2.5 million S

Potential first-in-class, selective nociceptin receptor (NOP) agonist that aims to provide safe, effective treatment for moderate to severe acute pain. Following successful Phase I results earlier this year demonstrating an excellent safety profile, the program has now progressed to Phase II. The randomized, double-blind, double-dummy, placebo- and active controlled, 2-part Phase II trial will evaluate the safety, tolerability and efficacy of this novel NOP agonist in patients post bunionectomy

On October 19, 2026, the first patients in the Phase 1/2 clinical trial ATL001-PII-CEP received their first dose and will continue on a daily oral dose over the coming months. On October 19, 2026, the first three patients with congenital erythropoietic porphyria (CEP) enrolled in the ATL001-PII-CEP clinical trial received their first dose of ATL-001, Atlas Molecular Pharma’s investigational oral drug for CEP. This is the first timeATL-001 h as been given to people with this severe, ultra-rare d

Oral olorofim was non-inferior to AmBisome® followed by standard of care (AmBisome®+SOC), with Day 42 all-cause mortality of 23.8% for olorofim versus 24.3% for AmBisome®+SOC in patients with invasive aspergillosis1 Enrolled patients had invasive aspergillosis for which standard mould-active azole therapy was either not appropriate (known or suspected azole resistance, intolerance to azole therapy, drug-drug interactions, or breakthrough infection while on azole) or had been ineffective1 Fewer p

Collaborators publish new peer-reviewed study identifying sex-specific effects of TUSC2 loss on mitochondrial function, protein homeostasis, and synaptic pathways, alongside molecular similarities with human brain Findings suggest that TUSC2 may play a foundational role in brain health Oct. 21, 2026 -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage biotechnology company developing gene therapies designed to restore tumor-suppressor function in cancer and insulin-pro

Saniona (OMX: SANION), a clinical-stage biopharmaceutical company focused on neurological and psychiatric disorders, today announces the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for SAN2465 for the treatment of major depressive disorder (MDD). The Phase 1 study is expected to be initiated by the end of 2026, contingent on FDA clearance of the IND application. “The IND submission for SAN2465 represents an important milestone for Sa

The US Food and Drug Administration (FDA) has granted Roche a label expansion for its ophthalmology therapy, Enspryng (satralizumab), in thyroid eye disease (TED), with the benefit of an at-home administration. This means that the interleukin 6 (IL-6) inhibitor is now greenlit for use in adults with TED – a condition where the body’s own cells attack the muscles, tear glands and connective tissues behind the eyes. Following its label expansion, healthcare providers can now prescribe Enspryng to

ADPKD is an inherited, progressive disorder where fluid-filled cysts expand in both kidneys. Credit: sasirin pamai/Shutterstock.com. US-based genetic medicines developer Estuary Biotherapeutics has launched after securing $103m in total committed financing for developing targeted gene therapies to treat kidney diseases. The capital will fund clinical proof-of-concept testing for the biotechnology company’s lead gene therapy candidates, EST-101 and EST-201, whilst advancing its platform for direc

The trial met the primary and secondary endpoints with statistically significant placebo-adjusted improvements at Week 3 in the YMRS total score (3.1 points; p=0.045) and CGI-BP Severity of Mania score (0.4 points; p=0.024) RAP-219–treated patients had a 15.4-point mean reduction in YMRS total score from baseline at Week 3 All 11 items measured by the YMRS improved numerically compared to placebo at Week 3, with improvements in irritability, thought content, disruptive-aggressive behavior, and s